- Home
- PASG vs RLYB Comparison
PASG vs RLYB Comparison
Compare PASG & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PASG | RLYB |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 28.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PASG | RLYB |
|---|---|---|
| Price | $8.04 | $8.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $24.80 | N/A |
| AVG Volume (30 Days) | 32.8K | ★ 135.3K |
| Earning Date | 03-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $0.28 | $0.22 |
| 52 Week High | $20.00 | $11.49 |
Technical Indicators
Market Signals| Indicator | PASG | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 52.08 |
| Support Level | $6.71 | $0.50 |
| Resistance Level | $8.94 | $11.49 |
| Average True Range (ATR) | 0.73 | 0.68 |
| MACD | 0.13 | -0.36 |
| Stochastic Oscillator | 83.74 | 21.84 |
Price Performance
Historical ComparisonAbout PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.